For weight recurrence following bariatric surgery, semaglutide 1 mg once a week outperforms liraglutide 3 mg once a day.

Published Date: 24 Apr 2023

The treatment of post-metabolic and bariatric surgery (MBS) weight recurrence has been shown to be more effective with semaglutide than liraglutide.

Read Full News

Latest News

Researchers develop innovative vascularized tumor model to advance cancer immunotherapy

A research team led by the Faculty of Dentistry at The University of Hong Kong (HKU) has developed a novel vascularized tumor model using a non-surgical injectable hydrogel system. This innovative approach provides a powerful ...

Immune-hot brain tumor subtype that defies survival expectations discovered

A research team has discovered a previously overlooked subtype of brain tumor termed IME IDH-mutant astrocytoma. Contrary to typical medical expectations, this subtype exhibits strong immune activity, classified as "immune‑hot," ...

Decades-old asthma theory challenged: Newly discovered molecules may be real drivers of disease

For decades, scientists have thought they understood the biochemical machinery that causes asthma—inflammation in the lungs that constricts airways and makes it hard to breathe.

Potential antibody therapy restricts the growth of aggressive and treatment-resistant breast cancers

A new potential antibody therapy strategy which restricts the growth of treatment-resistant breast cancers has been developed by scientists.

Existing drugs for tissue scarring could help avert melanoma relapses

Cellular changes that appear during melanoma and lead to treatment resistance can be reversed with drugs—potentially opening the door to new or more effective treatments for the deadly disease, according to new Cornell ...

Scientists develop one-product-fits-all immunotherapy for breast cancer

Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful therapies.

Todays Updates

COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment

The COVID-19 mRNA-based vaccines that saved 2.5 million lives globally during the pandemic could help spark the immune system to fight cancer. This is the surprising takeaway of a new study that we and our colleagues published ...

Todays Updates

COVID-19 mRNA vaccines could unlock the next revolution in cancer treatment

The COVID-19 mRNA-based vaccines that saved 2.5 million lives globally during the pandemic could help spark the immune system to fight cancer. This is the surprising takeaway of a new study that we and our colleagues published ...

Latest News

A research team led by the Faculty of Dentistry at The University of Hong Kong (HKU) has developed a novel vascularized tumor model using a non-surgical injectable hydrogel system. This innovative approach provides a powerful ...

A research team has discovered a previously overlooked subtype of brain tumor termed IME IDH-mutant astrocytoma. Contrary to typical medical expectations, this subtype exhibits strong immune activity, classified as "immune‑hot," ...

For decades, scientists have thought they understood the biochemical machinery that causes asthma—inflammation in the lungs that constricts airways and makes it hard to breathe.

A new potential antibody therapy strategy which restricts the growth of treatment-resistant breast cancers has been developed by scientists.

Cellular changes that appear during melanoma and lead to treatment resistance can be reversed with drugs—potentially opening the door to new or more effective treatments for the deadly disease, according to new Cornell ...

Triple-negative breast cancer is one of the most aggressive cancers. The name tells the story: It lacks the three main targets that make other types of breast cancers more treatable with powerful therapies.

News All Time

Triplet combinations of immunotherapy and targeted treatments as first-line therapy for advanced renal cell carcinoma

KEYMAKER-U03 is an international, multicenter, open-label, Phase I/II umbrella trial evaluating experimental combinations of pembrolizumab-based immunotherapy and targeted treatments for advanced clear cell renal cell carcinoma ...

Recurrence-free survival longer with nivolumab than ipilimumab in melanoma: Study

For patients with resected stage IIIB-C or stage IV melanoma, recurrence-free survival is longer with nivolumab than ipilimumab, according to a study published online Oct. 18 in the New England Journal of Medicine to coincide ...

Less than half of schoolkids at risk of food anaphylaxis in England prescribed adrenaline 'antidote'

Less than half of schoolchildren in England who are at risk of a serious and potentially life-threatening allergic reaction (anaphylaxis) to food were prescribed the antidote—an adrenaline [epinephrine] autoinjector, or ...

Immune-altering drug suppresses tumor-protecting cells and enhances stomach cancer treatment

Working with an international team of collaborators, scientists at Columbia University have found a way to shift the balance of a type of white blood cell inside a stomach tumor, causing the immune system to recognize and ...

ADC improves outcomes in advanced triple-negative breast cancer patients ineligible for immune checkpoint inhibitors

Patients with an aggressive form of breast cancer who are not candidates for immune checkpoint inhibitor therapy showed significantly improved progression-free survival when treated with the antibody drug conjugate sacituzumab ...

How multiple sclerosis harms a brain long before symptoms appear

By the time patients start seeking care for multiple sclerosis (MS), the disease has already been damaging their brains for years. But until recently, scientists didn't understand which brain cells were being targeted or ...

New generation of antibody-drug conjugates shows promise in early-stage HER2-positive breast cancer

In a landmark moment at the ESMO Congress 2025, pivotal studies have unveiled compelling evidence that a new class of anti-cancer agents—antibody-drug conjugates (ADCs)—can dramatically improve outcomes for patients with ...

Blood test guides post-surgical immunotherapy for muscle-invasive bladder cancer

Patients with muscle-invasive bladder cancer who test positive for circulating tumor (ct)DNA after surgery to remove the cancer benefit from immunotherapy with atezolizumab compared to placebo whereas ctDNA-negative patients ...

Scientists discover how cells protect the skin from inflammatory disease—paving the way for new treatments

Researchers at VIB and Ghent University have uncovered a key mechanism that protects the skin from harmful inflammation. The findings, published in Immunity, could open new avenues for treating chronic skin diseases and other ...

Combination of immunotherapy and targeted therapy boosts colorectal cancer survival, clinical trial finds

A new study led by UCLA investigators found that combining zanzalintinib, a targeted therapy drug, and atezolizumab, an immune checkpoint inhibitor, helped patients with metastatic colorectal cancer, the second most common ...

Targeted immunotherapy combination offers hope to older adults with leukemia

Researchers from the Alliance for Clinical Trials in Oncology have found that two targeted immunotherapy drugs lead to high remission rates and long survival with reasonable side effects for older patients with a tough-to-treat ...

VT3989 continues to show promising early results in patients with advanced mesothelioma

The first-in-class YAP-TEAD inhibitor VT3989 continued to be well tolerated and demonstrated notable initial antitumor activity, particularly in patients with refractory mesothelioma, according to results from a trial led ...

Supercharging immune cells to fight drug resistant bowel cancer

Scientists at University College London have engineered a rare type of immune cell to kill slow-growing bowel cancer cells that are resistant to current therapies, a breakthrough that could lead to new treatments in the future.

'Craters' on surface of melanoma cells mark tumor-killing hotspots, study reveals

New research published in Cell finds the existence of craters on the surface of melanoma cells that serve as immune hubs, becoming major sites for tumor killing. These craters could serve as good markers for immunotherapy ...

How bacteria in tumors drive treatment resistance in cancer

Researchers from The University of Texas MD Anderson Cancer Center have discovered a previously unknown mechanism that explains how bacteria can drive treatment resistance in patients with oral and colorectal cancer. The ...

Modified virus boosts cancer vaccine effectiveness in mouse experiments

Could a future vaccine against cancer be made better by an immune-boosting virus? Very likely, say Canadian scientists, who've proven its effectiveness in experiments on mice.

Recommended News For You

MRI can save rectal cancer patients from surgery, study suggests

Blinatumomab Plus Chemotherapy New Standard for Children With B-Cell ALL

Effective for localizing small, non-palpable breast lesions is ultrasound-guided localization with magnetic seeds.

Adding Targeted Agent to Perioperative Therapy for RCC May Improve Disease Control

Tafasitamab-Based Combination Boosts PFS in Relapsed/Refractory Follicular Lymphoma

Finding a clue to the origin of treatment-resistant leukemia in kids

Let's Talk Breast Density; Cancer, Movies, and Music; Treatment-Induced Aging?

Recommended Articles For You

The Genetics of Bernard Soulier Syndrome: What We Know so Far 

Unpacking the Importance of White Blood Cells (WBCs) in the Body  

Mastering Modern Oncology: Accreditation, Education, and Research Trends for 2025 

Omega-3 Fatty Acids as Molecular Adjuvants Against Chemoresistance in Breast Cancer 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Medicaid expansion tied to smaller declines in early-stage cancer detection

2.

Integrative palliative care is critical to improving mental health among pancreatic cancer patients

3.

Researchers identify a novel biomarker linked to renal cancer recurrence

4.

Integrating MRD in Myeloma: Guidance for Therapy Escalation and De-escalation

5.

Will a Mindfulness-Based Treatment for Depression Increase Recovery Rates?

1.

Therapeutic Innovations Through Germline Predisposition in Acute Leukemias and Myeloid Neoplasms

2.

Liposomal Doxorubicin and Mitomycin in Modern Cancer Treatment

3.

A Breakthrough in Multiple Myeloma: Darzalex Delays Disease Progression by 51%

4.

Unleashing Precision Medicine: CRISPR-Cas9 Gene Editing in Hematopoietic Stem Cells

5.

Mastering Prostate Cancer Care: CME, Certification, Digital Tools, and Evidence-Based Strategies

1.

International Lung Cancer Congress®

2.

Genito-Urinary Oncology Summit 2026

3.

Future NRG Oncology Meeting

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Current Scenario of Cancer- Final Discussion on the Importance of Genomic Testing & Advancement in Diagnosis and Treatment

2.

Targeting Oncologic Drivers: A New Approach to Lung Cancer Treatment

3.

Exploring Best Possible Treatment Strategies in Advanced Urothelial Carcinoma- A Panel Discussion

4.

Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update) - Part IV

5.

Navigating the Complexities of Ph Negative ALL - Part IV

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot